Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19442309 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2MEN1KMT2ALMNAPOLB | |
| SCHEMBL27974505 | 0.83 | SMN1; SMN2 (0.70) | SMN1; SMN2MEN1KMT2AGLARAB9A | |
| SCHEMBL7902465 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2MEN1KMT2ALMNAHSD17B10 | |
| SCHEMBL19766684 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2MEN1KMT2AGLALMNA | |
| SCHEMBL2921484 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2MEN1KMT2AGLARAB9A | |
| SCHEMBL21214009 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2MEN1KMT2ALMNAHSD17B10 | |
| SCHEMBL31053543 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2MEN1KMT2AGLARAB9A | |
| SCHEMBL24701188 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2GLARAB9ALMNATSHR | |
| SCHEMBL26448356 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2POLB | |
| SCHEMBL23032902 | 0.78 | SMN1; SMN2 (0.63) | SMN1; SMN2MEN1KMT2AGLARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-14 | — | — | US | disclosed |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-14 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-9783524-B2 | Protein tyrosine kinase modulators and methods of use | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-9783524-B2 | Protein tyrosine kinase modulators and methods of use | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-05-26 | — | — | US | disclosed |
| CN-103880575-B | Method for preparing beta-amino amide derivatives | UNIV TAIZHOU | 2015-06-03 | — | — | CN | disclosed |
| CN-103880575-A | Method for preparing beta-amino amide derivatives | UNIV TAIZHOU | 2014-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | ALK, EGFR, ERBB2 | SMN1; SMN2 4557/4885MEN1 4820/4885KMT2A 2779/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | SMN1; SMN2 4718/4885MEN1 3963/4885KMT2A 462/4885 |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | DMPK, PDXK, NIM1K | SMN1; SMN2 439/4885MEN1 488/4885KMT2A 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.